Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai: Overseas Sales Up 53%, Accounting for 42.9% of Total Sales
June 3, 2002
- Taiho Aims at Sales of \140 Bil. in 2004
June 3, 2002
- Daiichi: Record-high Sales, Profits Thanks to Cravit
June 3, 2002
- BUSINESS NEWS IN BRIEF
June 3, 2002
- Taisho: Sales Down 1.1% due to Slump of OTC Drugs
June 3, 2002
- NEW PRODUCTS
June 3, 2002
- Banyu: Nu-lotan Contributes to Good Sales, Profits
June 3, 2002
- 9 Drugs Including Elaspol to Be Included in NHI List
June 3, 2002
- Sumitomo: Mainstays Drive Sales, Profits
June 3, 2002
- Korosho Listens to Opinions from Industry on Its Proposed Industry Vision
June 3, 2002
- Santen: Overseas Sales Make Up for Poor Domestic Performance
June 3, 2002
- REGULATORY NEWS IN BRIEF
June 3, 2002
- Asahi Kasei: Flivas, Toledomin Prop Up Drug Business
June 3, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
June 3, 2002
- All Major Listed Wholesalers Report Increases in Sales
June 3, 2002
- PII Results of Iressa Reported at ASCO
June 3, 2002
- We Are in Predawn of Radical Reform: Mr Nagayama of JPMA
June 3, 2002
- New Shionogi Cephem Antibiotic Shows Good Effects on MRSA
June 3, 2002
- Dainippon Licenses Ca Antagonist from Recordati
June 3, 2002
- Panasonic Develops High-throughput Drug Screening Technology
June 3, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…